NCT05978102View on ClinicalTrials.gov

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Advanced Solid Tumor
Interventions
DRUG

STI-7349

Administered by intravenous infusion (IV)

DRUG

Pembrolizumab

Administered by intravenous infusion (IV)

DRUG

Standard treatment（SoC）

Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.

DRUG

approved PD-1/PD-L1 inhibitors (e.g., Tislelizumab, etc.)

Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines or the corresponding drug Labeling.

Trial Locations (1)

Unknown

RECRUITING

The Fourth Affiliated Hospital of Zhejiang University School of Medicine., Yiwu

All Listed Sponsors
lead

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

OTHER